sorafenib has been researched along with bms 536924 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (bms 536924) | Trials (bms 536924) | Recent Studies (post-2010) (bms 536924) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 41 | 0 | 20 |
| Protein | Taxonomy | sorafenib (IC50) | bms 536924 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 1.6 | |
| Insulin receptor | Homo sapiens (human) | 0.073 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.341 | |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | 0.1066 | |
| Hepatocyte growth factor receptor | Homo sapiens (human) | 4.87 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.1418 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 1.2 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 2 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 1.4 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.182 | |
| Focal adhesion kinase 1 | Homo sapiens (human) | 0.15 | |
| Cysteinyl leukotriene receptor 1 | Cavia porcellus (domestic guinea pig) | 0.5 | |
| Insulin-like growth factor 1 receptor | Mus musculus (house mouse) | 0.11 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, AY; Wang, M | 1 |
1 other study(ies) available for sorafenib and bms 536924
| Article | Year |
|---|---|
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |